PMID- 22909227
OWN - NLM
STAT- MEDLINE
DCOM- 20130326
LR  - 20221207
IS  - 1477-7819 (Electronic)
IS  - 1477-7819 (Linking)
VI  - 10
DP  - 2012 Aug 21
TI  - The detection of hTERC amplification using fluorescence in situ hybridization in 
      the diagnosis and prognosis of cervical intraepithelial neoplasia: a case control 
      study.
PG  - 168
LID - 10.1186/1477-7819-10-168 [doi]
AB  - BACKGROUND: Currently the routine non-invasive screening methods for cervical 
      intraepithelial neoplasia (CIN) and cervical cancer are Thinprep cytology test 
      (TCT) and human papillomavirus testing. However, both methods are limited by the 
      high false positive and false negative rates and lack of association with 
      patients' prognosis, especially for the early detection of pro-malignant CIN. The 
      aim of the study was to investigate the role of genomic amplification of human 
      telomerase gene (hTERC) in the diagnosis and prognosis of CIN. METHODS: The study 
      group consisted of specimens of exfoliated cervical cells from 151 patients, 
      including 27 with CIN I, 54 with CIN II/III, 17 with carcinoma in situ, and 28 
      with invasive squamous carcinoma, as well as 25 patients who were at 2-year 
      follow-up after either Loop Electrosurgical Excision treatment (n = 11) or 
      radical surgery (n = 14). hTERC amplification was detected by dual-color 
      interphase fluorescence in situ hybridization (FISH), and the results were 
      compared with TCT and histologic examination. The final diagnosis was determined 
      by the pathological examination. The control group consisted of specimens of 
      exfoliated cervical cells from 40 normal women. RESULTS: The percentage of 
      cervical exfoliated cells with positive hTERC amplification and incidence rates 
      of hTERC amplification were 9.2% +/- 4.6% and 44.4% (12/27) respectively in 
      patients with CIN I; 16.0% +/- 14.4% and 85.1% (46/54) in patients with CIN II/III; 
      19.7% +/- 13.3% and 88.3% (15 /17) in patients with carcinoma in situ; 47.0% +/- 
      25.2% and 100% (28/28)in patients with invasive squamous carcinoma. There was 
      statistically significant difference between the control and study group (P 
      <0.01), and between the patients with various diseases within the study group (P 
      <0.05). CONCLUSION: The detection of genomic amplification of hTERC using FISH is 
      a non-invasive and effective approach for CIN.
FAU - Yin, Geping
AU  - Yin G
AD  - Department of Obstetrics & Gynecology, Jinan Military General Hospital, 25 Shifan 
      Road, Jinan 250031, China. ygpwylll@hotmail.com
FAU - Li, Juan
AU  - Li J
FAU - Zhu, Tongyu
AU  - Zhu T
FAU - Zhao, Xiaoli
AU  - Zhao X
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120821
PL  - England
TA  - World J Surg Oncol
JT  - World journal of surgical oncology
JID - 101170544
RN  - 0 (telomerase RNA)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.7.49 (Telomerase)
SB  - IM
MH  - Adult
MH  - Carcinoma in Situ/*diagnosis/genetics
MH  - Carcinoma, Squamous Cell/*diagnosis/genetics
MH  - Case-Control Studies
MH  - Cervix Uteri/metabolism/pathology
MH  - Female
MH  - Follow-Up Studies
MH  - *Gene Amplification
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Prognosis
MH  - RNA/*genetics
MH  - Retrospective Studies
MH  - Telomerase/*genetics
MH  - Uterine Cervical Neoplasms/*diagnosis/genetics
MH  - Uterine Cervical Dysplasia/*diagnosis/genetics
PMC - PMC3485165
EDAT- 2012/08/23 06:00
MHDA- 2013/03/27 06:00
PMCR- 2012/08/21
CRDT- 2012/08/23 06:00
PHST- 2012/01/24 00:00 [received]
PHST- 2012/07/23 00:00 [accepted]
PHST- 2012/08/23 06:00 [entrez]
PHST- 2012/08/23 06:00 [pubmed]
PHST- 2013/03/27 06:00 [medline]
PHST- 2012/08/21 00:00 [pmc-release]
AID - 1477-7819-10-168 [pii]
AID - 10.1186/1477-7819-10-168 [doi]
PST - epublish
SO  - World J Surg Oncol. 2012 Aug 21;10:168. doi: 10.1186/1477-7819-10-168.